Ocular Therapeutix Company Profile
✉ Email this page to a colleague
What is the competitive landscape for OCULAR THERAPEUTIX, and when can generic versions of OCULAR THERAPEUTIX drugs launch?
OCULAR THERAPEUTIX has one approved drug.
There are three US patents protecting OCULAR THERAPEUTIX drugs.
There are twenty-five patent family members on OCULAR THERAPEUTIX drugs in six countries and three supplementary protection certificates in two countries.
Summary for Ocular Therapeutix
| International Patents: | 25 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Ocular Therapeutix
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | 8,563,027 | See Plans and Pricing | See Plans and Pricing | ||||
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | 9,254,267 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ocular Therapeutix Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2977830 | See Plans and Pricing |
| China | 102395401 | See Plans and Pricing |
| European Patent Office | 2427233 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ocular Therapeutix Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1429780 | 13C0012 | France | See Plans and Pricing | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| 1581193 | SPC/GB12/047 | United Kingdom | See Plans and Pricing | PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727 |
| 1429780 | SPC/GB12/058 | United Kingdom | See Plans and Pricing | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
